HanchorBio Gets FDA Green Light for Innovative Immunotherapy HCB303 to Target Advanced Tumors

HanchorBio Secures FDA Clearance for HCB303

HanchorBio, Inc., a notable player in the biotechnology sector, has made headlines with its recent announcement regarding the U.S. Food and Drug Administration's (FDA) approval for the investigational new drug (IND) application of HCB303. This marks a significant milestone for the company, which focuses on developing advanced immunotherapies for cancer patients and those suffering from immune-mediated diseases.

Background and Significance of HCB303

The clearance granted by the FDA paves the way for HanchorBio to launch Phase 1 clinical trials, which will be the first-of-its-kind human tests for HCB303. This novel trispecific immunotherapy is designed to enhance immune responses against cancer, specifically targeting advanced solid tumors. It employs an innovative mechanism that incorporates a unique TIGIT-Fc ligand-trap strategy, addressing key pathways in tumor immune evasion, namely TIGIT/PVR, PD-L1/PD-1, and CD47/SIRPα pathways.

What sets HCB303 apart from traditional therapies is its design to simultaneously preserve the CD226 activating axis while effectively blocking PD-L1 and SIRPα-mediated inhibitory signals. In essence, HCB303 aims to improve T-cell and Natural Killer (NK) cell activity, bolstering the body’s innate and adaptive immune responses against tumors.

The Trispecific Approach

HCB303’s trispecific nature transparently illustrates HanchorBio’s commitment to pushing the boundaries of cancer immunotherapy. Unlike conventional anti-TIGIT antibodies, which primarily focus on inhibiting the TIGIT receptor signaling, HCB303 intercepts TIGIT ligands such as PVR/CD155 and CD112. By strategically trapping these ligands, HCB303 works to dampen the immune inhibition traditionally associated with TIGIT, all while preserving crucial activating signals needed for an effective immune response.

According to Scott Liu, PhD, the Founder and Chairman of HanchorBio, this TIGIT-Fc strategy offers a biologically superior path compared to traditional receptor blockade. “HCB303 was designed to go further—intercepting immune-inhibiting TIGIT ligands and preserving the CD226 activating axis,” Liu explained. This innovative approach aims to create a more integrated response to cancer within the tumor microenvironment.

Phase 1 Clinical Trials

The FDA's clearance for HCB303 comes on the heels of pre-IND feedback received in August 2026. The upcoming clinical trial, designated as HCB303-ONC-101, will examine the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-tumor activity of HCB303 among a population of patients diagnosed with complicated solid tumors who lack conventional treatment options. These trials are set to be multifaceted and multi-regional, enhancing the study's scope and potential impact.

HanchorBio's President and CMO, Alvin Luk, PhD, MBA, emphasized the importance of this achievement, stating, “The FDA clearance moves HCB303 from a differentiated biological hypothesis into clinical testing.” The focus moving forward is to rigorously evaluate whether this innovative therapeutic can yield significant clinical results.

As HanchorBio continues to pioneer the development of advanced biologics, with HCB301 already in trials and HCB303 set to begin, the potential of its FBDB™ platform remains high. This platform is designed to produce unique multispecific therapeutics, targeting multiple immune pathways to enhance treatment efficacy.

Conclusion

In summary, the FDA clearance for HCB303 positions HanchorBio at the forefront of cancer treatment innovation. With the initiation of Phase 1 clinical trials on the horizon, the biotechnology community and cancer patients alike will be watching closely to see if HCB303 can indeed translate its promising scientific strategy into real-world clinical benefits. As HanchorBio forges ahead, it highlights the exciting possibilities that next-generation immunotherapy holds for oncology, pushing boundaries in the fight against cancer effectively and efficiently.